数据四舍五入，查看更多财务数据>> 三、分红送配方案情况 二、前10名无限售条件股东持股情况 本次公司不分配不转赠。 一、主要会计数据和财务指标 前十大流通股东累计持有： 504.07万股，累计占流通股比： 12.76%，较上期变化： 504.07万股。 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | - | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0593 | 0.0654 | -9.33 | - | | 每股净资产（元） | 3.07 | 0 | 0 | - | | 每股公积金(元) | 1.44 | 0 | 0 | - | | 每股未分配利润(元) | 0.59 | | 0 | - | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.84 | 0.77 | 9.09 | - | | 净利润(亿元) | 0.24 | 0.24 | 0 | - | | 净资产收益率(%) | 1.96 | | 0 | - | | 名称 | 持有数量(万股) | 占总股本比例 | 增减 ...

根据《公司法》《公司章程》等有关规定，此次黄漫履先生辞去董事会秘书职务不会对公司日常管理、 生产经营产生重大影响。黄漫履先生在担任公司董事会秘书期间恪尽职守、勤勉尽责，公司及董事会对 黄漫履先生任职期间为公司所做的贡献表示衷心的感谢！ 二、关于聘任董事会秘书的相关情况 证券代码：688758 证券简称：赛分科技 公告编号：2025-011 苏州赛分科技股份有限公司 关于董事会秘书辞职及聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、关于董事会秘书辞职的相关情况 苏州赛分科技股份有限公司（以下简称"公司"）董事会近期收到公司董事会秘书黄漫履先生提交的书面 辞职报告。黄漫履先生因个人原因，申请辞去公司董事会秘书职务，辞职后黄漫履先生将不再担任公司 任何职务。根据《公司法》《公司章程》等规定，上述辞职报告自送达董事会之日起生效。 联系地址：江苏省苏州工业园区集贤街11号赛分科技 特此公告。 苏州赛分科技股份有限公司 董事会 2025年4月4日 王中蕾，女，1995年出生，中国国籍，无境外永久居留权，中共 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688758 证券简称：赛分科技 公告编号：2025-011 苏州赛分科技股份有限公司 关于董事会秘书辞职及聘任董事会秘书的公告 王中蕾女士已参加上海证券交易所科创板上市公司董事会秘书任前培训并 完成测试，已取得董事会秘书任职培训证明，具备履行董事会秘书职责所必需的 专业知识和工作经验，具有良好的职业道德和个人品质，不存在相关法律法规规 定的禁止任职情形，符合《公司法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法 规及规范性文件规定的董事会秘书任职资格，其个人简历详见附件。 董事会秘书王中蕾女士的联系方式如下： 联系电话：0512-69369067 电子邮箱：ir@sepax-tech.com.cn 联系地址：江苏省苏州工业园区集贤街 11 号赛分科技 一、关于董事会秘书辞职的相关情况 苏州赛分科技股份有限公司（以下简称"公司"）董事会近期收到公司董事 会秘书黄漫履先生提交的书面辞职报告。黄漫履 ...

纳微科技在色谱领域的发展历程和核心竞争力是什么？ 纳微科技在色谱领域的发展历程可以追溯到其早期在美国实验室的客服业务。 公司在美国建立了强大的品牌影响力，尤其是在工业纯化方面，近年来产品数 量和收入增长迅速。纳微科技的核心竞争力主要体现在其长期积累的技术优势 和市场拓展能力。公司在分析色谱和工业纯化领域均具备研发及规模化生产能 力，特别是在工业纯化端已得到验证。此外，公司还积极拓展海外市场，利用 赛分科技 20250313 摘要 Q&A • 赛分科技营收快速增长，2019 年至 2024 年营收复合增长率达 34%，利润端 扣非归母净利润复合增长率高达 86%，主要受益于分析色谱和工业纯化两 大板块的驱动，其中工业纯化板块自 2020 年起快速增长，成为核心业务。 • 公司毛利率呈波动上升趋势，分析色谱业务毛利率稳定在 70%以上，工业 纯化板块中，除硅胶基质填料外，其余产品毛利率较高。期间费用控制良 好，整体呈下降趋势，主要得益于营收规模增长和有效的费用控制。 • 色谱填料是公司核心业务，其关键参数包括孔径、粒径大小及其分布等机 制材料因素，以及与分离模式和选择性相关的表面修饰官能团。公司在硅 胶、琼脂糖和 ...

Investment Rating - The report gives an "Accumulate" rating for the company for the first time, with a target price of 18.88 CNY based on a 59 times P/E ratio for 2026 [5][8]. Core Views - The company is positioned as a leading domestic chromatography manufacturer, entering a new growth cycle, with significant revenue and profit growth expected in the coming years [11][16]. - The industrial purification segment is identified as the core growth driver, with strong downstream demand and plans for new capacity to enhance market share [11][12]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of 0.21 CNY, 0.27 CNY, and 0.32 CNY for 2024, 2025, and 2026 respectively, with revenues expected to grow from 3.15 billion CNY in 2024 to 4.49 billion CNY in 2026 [5][7]. - The report highlights a compound annual growth rate (CAGR) of 34% for revenue from 2019 to 2024 and an impressive 86% CAGR for net profit from 2020 to 2024 [25][11]. Company Overview - The company, established in 2002 in the USA, specializes in analytical chromatography and industrial purification chromatography fillers, with a strong R&D and production capability in both fields [11][16]. - The company has a clear ownership structure and has attracted significant strategic investors, enhancing its market position [18][19]. Product Competitiveness - The company’s core products in both industrial purification and analytical chromatography are competitive, with strong performance metrics compared to imported products [11][12]. - The industrial purification segment has rapidly gained traction since 2020, becoming the company's main business and growth engine [25][11]. Market Demand and Growth Potential - There is a robust demand for the company’s products, with a significant increase in early clinical projects and a strong pipeline of late-stage clinical and commercial projects [11][12]. - The report notes a trend towards domestic substitution in the chromatography market, driven by cost pressures and the need for stable supply chains [11][12]. Financial Performance - The company’s revenue increased from 0.74 billion CNY in 2019 to 3.15 billion CNY in 2024, with a notable increase in profitability [25][27]. - The gross margin has shown improvement, with the company achieving a leading position in the industry [35][36].

Investment Rating - The report gives an "Accumulate" rating for the company for the first time, with a target price of 18.88 CNY based on a 59 times P/E ratio for 2026 [5][8]. Core Views - The company is positioned as a leading domestic chromatography manufacturer, entering a new growth cycle with rapid revenue and profit growth, particularly in the industrial purification segment, which has become the core business [11][25]. - The company has strong competitive advantages in its core products, with both industrial purification and analytical chromatography segments showing robust performance and collaboration with key clients [11][12]. - There is significant growth potential driven by strong downstream demand and a trend towards domestic substitution in the chromatography market, especially in the context of rising cost pressures from drug price reductions [11][12]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of 0.21 CNY, 0.27 CNY, and 0.32 CNY for the years 2024, 2025, and 2026 respectively, with a rapid increase in revenue expected from the industrial purification segment [5][11]. - Revenue is expected to grow from 2.13 billion CNY in 2022 to 4.49 billion CNY in 2026, reflecting a compound annual growth rate (CAGR) of 34% from 2019 to 2024 [7][25]. - The net profit attributable to the parent company is forecasted to rise from 470 million CNY in 2022 to 1.33 billion CNY in 2026, with a CAGR of 86% from 2020 to 2024 [7][25]. Company Overview - The company, established in 2002 in the United States, specializes in analytical chromatography and industrial purification chromatography fillers, and is one of the few companies with R&D and large-scale production capabilities in both fields [11][16]. - The company has a clear equity structure and has attracted significant strategic investors, enhancing its market position and operational capabilities [18][19]. Product Competitiveness - The company’s industrial purification products are primarily used in the clinical research and industrial production phases of drug development, with a comprehensive range of over 100 products covering various separation modes and application scenarios [46][50]. - The analytical chromatography segment has a stable revenue structure, primarily driven by size exclusion chromatography columns, while the industrial purification segment has shown significant growth since 2020 [32][46]. Market Demand and Growth Potential - The company has accumulated a substantial number of early-stage projects, with 106 early clinical projects and 56 late clinical and commercial projects expected to drive demand [11][12]. - The domestic chromatography and industrial purification market has a high concentration and low domestic substitution rate, indicating significant growth opportunities as the trend towards domestic products increases [11][12].

Financial Performance - The company achieved total operating revenue of 315.46 million RMB, a year-on-year increase of 28.65%[3] - The net profit attributable to the parent company was 85.16 million RMB, reflecting a year-on-year growth of 62.25%[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 77.85 million RMB, up 69.15% year-on-year[3] - Basic earnings per share increased to 0.2324 RMB, a rise of 62.29% compared to the previous year[3] - The weighted average return on equity rose to 8.17%, an increase of 2.75 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were 1,182.31 million RMB, representing a year-on-year growth of 7.29%[7] - The equity attributable to the parent company was 1,088.06 million RMB, an increase of 9.07% year-on-year[7] Market Expansion and Client Management - The company expanded its market by successfully onboarding multiple new clients in the industrial purification chromatography medium supply chain[8] - The company maintained existing clients and actively pursued new projects, leading to increased operational scale and profitability[10] Cost Management - The company emphasizes the importance of cost reduction and efficiency improvement, which contributed to enhanced profit levels[10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州赛分科技股份有限公司（以下简称"公司"）第二届董事会2025年第一次会议于2025年2月14日以现 场结合通讯方式在公司会议室召开。会议通知和会议资料已于2025年2月7日以电子邮件方式发出。本次 会议由董事长黄学英先生主持，会议应出席董事9人，实际出席董事9人，公司监事和高级管理人员列席 了会议。本次会议的通知和召开程序符合《中华人民共和国公司法》《苏州赛分科技股份有限公司章 程》的相关规定，本次会议及其决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于调整募集资金投资项目拟投入募集资金金额的议案》 表决结果：同意9票、反对0票、弃权0票。 公司首次公开发行股票募集资金总额低于计划募集资金金额，为保障募投项目的顺利实施，公司根据实 际募集资金情况，对本次募集资金项目投入金额进行调整，募集资金不足部分由公司以自有资金等方式 解决，具体情况如下： 单位：万元 公司独立董事就本事项发表了同意的独立意见。保荐人对本事项发表了无异议的核查意见。本 ...

中信证券股份有限公司 关于苏州赛分科技股份有限公司 使用募集资金向全资子公司提供借款以实施募投项目的核 查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为苏州赛分 科技股份有限公司（以下简称"赛分科技"、"公司"）首次公开发行股票并在科 创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所股票 上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定，对公司 拟以提供借款的形式向全资子公司赛分科技扬州有限公司（以下简称"扬州赛分"） 提供资金以实施募集资金投资项目（以下简称"募投项目"）事项进行了审慎核 查，具体核查情况如下： 一、募集资金基本情况 上述募集资金已于 2025 年 1 月 6 日划至公司指定账户，容诚会计师事务所 （特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验，并于 2025 年 1 月 7 日出具了《苏州赛分科技股份有限公司验资报告》（容诚验字 [2025]210Z0003 号）（以 ...

中信证券股份有限公司 关于苏州赛分科技股份有限公司 由于公司首次公开发行股票募集资金净额低于《苏州赛分科技股份有限公司 首次公开发行股票并在科创板上市招股说明书》中披露的拟投入募集资金金额。 为保证募投项目的顺利实施和募集资金的高效使用，公司根据实际募集资金情况， 对本次募集资金项目拟投入金额进行调整，募集资金不足部分由公司以自有资金 等方式解决，具体情况如下： 1 单位：万元 | | 募投项目名称 | 项目实施单 | 募投项目投 | 调整前募集资金 | 调整后募集资金 | | --- | --- | --- | --- | --- | --- | | | | 位 | 资总额 | 拟投入金额 | 拟投入金额 | | 1 | 20万升/年生物医 药分离纯化用辅 | 扬州赛分 | 41,467.68 | 33,423.41 | 16,580.13 | | | 料 | | | | | | 2 | 研发中心建设项 | 赛分科技、 | 19,816.22 | 19,499.25 | - | | | 目 | 赛分生科 | | | | | 3 | 补充流动资金 | 赛分科技 | 27,077.34 | 27,077.34 ...